碘难治性分化型甲状腺癌靶向治疗新进展

Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer

近年来,靶向治疗为碘难治性分化型甲状腺癌带来了革命性的突破。新型靶向药物的研发,让更多晚期分化型甲状腺癌患者获得了更好的生存。以索拉非尼和仑伐替尼为代表的多靶点小分子酪氨酸激酶抑制剂显著提升了患者的无进展生存期。与此同时,靶向BRAF及靶向RET的新型酪氨酸激酶抑制剂同样也取得了瞩目的疗效,丰富了甲状腺癌的治疗手段。本文就靶向治疗在碘难治性分化型甲状腺癌中的最新研究进展进行综述。

Targeted therapy has brought revolutionary breakthroughs for radioiodine-refractory differentiated thyroid cancer.New targeted drugs have prolonged the survival of patients with advanced differentiated thyroid cancer.Multiple tyrosine kinase inhibitors,represented by sorafenib and lenvatinib,have remarkably improved the progression-free survival of patients.Novel tyrosine kinase inhibitors targeting BRAF and RET mutation have also achieved remarkable curative effects,greatly enriching the treatment methods for thyroid cancer.This article reviews the latest research progress on targeted therapy in radioiodine-refractory differentiated thyroid cancer.